Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease
العنوان: | Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease |
---|---|
المؤلفون: | Ejvind Frausing Hansen, Jens-Ulrik Stæhr Jensen, Therese S. Lapperre, Imane Achir Alispahic, Josefin Eklöf, Torgny Wilcke, Niels Seersholm, Howraman Meteran, J. M. Bangsborg, Pradeesh Sivapalan, Ram Benny Dessau, Ulrich Stab Jensen, Mohamad Isam Saeed, Rikke Sørensen, Truls Sylvan Ingebrigtsen, Christian Østergaard, Jonas Bredtoft Boel |
المصدر: | Eklöf, J, Ingebrigtsen, T S, Sørensen, R, Saeed, M I, Alispahic, I A, Sivapalan, P, Boel, J B, Bangsborg, J, Ostergaard, C, Dessau, R B, Jensen, U S, Hansen, E F, Lapperre, T S, Meteran, H, Wilcke, T, Seersholm, N & Jensen, J-U S 2022, ' Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease ', Thorax, vol. 77, no. 6, pp. 573-580 . https://doi.org/10.1136/thoraxjnl-2021-217160 Eklöf, J, Ingebrigtsen, T S, Sørensen, R, Saeed, M I, Alispahic, I A, Sivapalan, P, Boel, J B, Bangsborg, J, Ostergaard, C, Dessau, R B, Jensen, U S, Hansen, E F, Lapperre, T S, Meteran, H, Wilcke, T, Seersholm, N & Jensen, J U S 2022, ' Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease ', Thorax, vol. 77, no. 6, pp. 573-580 . https://doi.org/10.1136/thoraxjnl-2021-217160 |
بيانات النشر: | BMJ, 2021. |
سنة النشر: | 2021 |
مصطلحات موضوعية: | Pulmonary and Respiratory Medicine, COPD, medicine.medical_specialty, business.industry, Respiratory infection, medicine.disease, Pneumonia, respiratory infection, Internal medicine, Propensity score matching, Epidemiology, Cohort, medicine, Outpatient clinic, COPD epidemiology, business, Cohort study |
الوصف: | BackgroundInhaled corticosteroids (ICS) are commonly used to treat COPD and are associated with increased risk of pneumonia. The aim of this study was to assess if accumulated use of ICS is associated with a dose-dependent risk of a positive airway culture with Pseudomonas aeruginosa in patients with COPD.MethodsWe conducted a multiregional epidemiological cohort study including Danish COPD patients followed in outpatient clinics during 2010–2017. ICS use was categorised based on accumulated prescriptions redeemed 365 days prior to cohort entry. Cox proportional hazard regression model was used to estimate the risk of acquiring P. aeruginosa. Propensity score matched models were used as sensitivity analyses.ResultsA total of 21 408 patients were included in the study, of which 763 (3.6%) acquired P. aeruginosa during follow-up. ICS use was associated with a dose-dependent risk of P. aeruginosa (low ICS dose: HR 1.38, 95% CI 1.03 to 1.84, p=0.03; moderate ICS dose: HR 2.16, 95% CI 1.63 to 2.85, pConclusionUse of ICS in patients with COPD followed in Danish outpatient clinics was associated with a substantially increased and dose-dependent risk of acquiring P. aeruginosa. Caution should be taken when administering high doses of ICS in severely ill patients with COPD. These results should be confirmed in comparable cohorts and other settings. |
وصف الملف: | application/pdf |
تدمد: | 1468-3296 0040-6376 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4327accb656e5ca5ac0c6aabce6cb6e4 https://doi.org/10.1136/thoraxjnl-2021-217160 |
حقوق: | OPEN |
رقم الأكسشن: | edsair.doi.dedup.....4327accb656e5ca5ac0c6aabce6cb6e4 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 14683296 00406376 |
---|